Agreement - May 19, 2026
Hansa Biopharma in EUR 115 million licensing agreement
Hansa Biopharma and SERB S.A. have announced an exclusive licensing agreement for development and commercialization of IDEFIRIX (imlifidase) in the European Union (EU), United Kingdom (UK), Switzerland, Norway, Liechtenstein, Iceland and MENA (Middle East and North Africa) regions.
Agreement - April 15, 2026
Novo Nordisk partners with OpenAI
The partnership will apply advanced AI capabilities to analyse complex datasets, identify promising drug candidates, and reduce the time required to move from research to patient, the company states.
Agreement - March 25, 2026
Genovis in non-exclusive license agreement with US biotech company
Genovis has entered into a non-exclusive, worldwide license agreement with a US-based private biotech company, granting rights to use Genovis’ EndoS2 enzyme technology for the research, development, manufacture, and commercialization of antibody-drug conjugate (ADC) therapeutics.
Agreement - March 23, 2026
Mendus signs agreement with Olivia Newton-John Cancer Research Institute
Mendus has entered into an agreement with the Olivia Newton-John Cancer Research Institute (ONJCRI), an Australian cancer research institute, to support the DIVA trial with the company’s lead product vididencel in acute myeloid leukemia (AML).
Agreement - February 23, 2026
Affibody signs Letter of Intent with SHINE Technologies
A Letter of Intent (LOI) has been signed with SHINE Technologies as an additional supplier of non-carrier-added Lutetium-177 (n.c.a. Lu-177).
Agreement - February 16, 2026
Ribocure in global licensing agreement
Suzhou Ribo Life Science and its Swedish subsidiary Ribocure Pharmaceuticals have entered into an exclusive worldwide licensing agreement with Madrigal Pharmaceuticals for six pre-clinical small interfering RNA (siRNA) programs for the treatment of metabolic dysfunction-associated steatohepatitis (MASH).